Two novel cancer immunotherapy targets in NatureMedicine Siglec15 as a critical immune suppressor identified by Lieping Chen team httpswww.nature.comarticless415910190374xÂQPCTL as an enzymatic modifier of the CD47 SIRP axishttps

Two novel cancer #immunotherapy targets in @NatureMedicine Siglec-15 as a critical immune suppressor, identified by Lieping Chen team https://www.nature.com/articles/s41591-019-0374-x … QPCTL as an enzymatic modifier of the CD47- SIRPα axis https:

Two novel cancer #immunotherapy targets in @NatureMedicine Siglec-15 as a critical immune suppressor, identified by Lieping Chen team https://www.nature.com/articles/s41591-019-0374-x … QPCTL as an enzymatic modifier of the CD47- SIRPα axis https://www.nature.com/articles/s41591-019-0356-z … pic.twitter.com/G4WdnZpekv

More From BioPortfolio on "Two novel cancer #immunotherapy targets in @NatureMedicine Siglec-15 as a critical immune suppressor, identified by Lieping Chen team https://www.nature.com/articles/s41591-019-0374-x … QPCTL as an enzymatic modifier of the CD47- SIRPα axis https:"